Valiant Laboratories Limited
Start Date27-09-2023
Application Timing10am-6pm
Price Range₹133 - ₹140
Min Qty105
Min. Investment₹13965
Listing Date06-10-2023
Close Date03-10-2023

About Valiant Laboratories Limited

They are an Active Pharmaceutical Ingredient (API) / Bulk Drug company manufacturing Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. 

They manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of our customers.

Our manufacturing facility is located at Palghar, Maharashtra, spread over 2,000 sq. mts with an aggregate annual total installed capacity of 9,000 MT per annum. 

Their in-house R&D Facility is equipped with analytical laboratory and infrastructure for developmental activities in existing products.

Why To Invest in Valiant Laboratories Limited

Valiant Laboratories is a pharmaceutical ingredient manufacturing company in India manufacturing Paracetamol.

The IPO proceeds will be used to fund capex requirements for new facilities and working capital requirements.

Strengths And Risks
Strategically located Manufacturing Facility: : Their Manufacturing Facility is strategically located at a distance of about 150 Kms. from JNPT and registered office at Mumbai, which ensures that they have ready access to port facilities for import & export.
Reducing dependence on import of raw materials: : There is a decreasing trend of import of raw material. They are purchasing it through promoter group company i.e. Valiant Organics Limited which leads to better coordination, competitive pricing, eliminating hefty transportation and reduced delivery transit time.
Experienced promoters and strong management team: : Shantilal Shivji Vora, Promoter and Non-Executive Director of the Company and a first-generation entrepreneur has been associated with Company (including as partner of M/s. Bharat Chemicals) since 1998. He has a rich experience of over 45 years in the chemical and pharmaceutical industry.
Strong Financial Performance: : They strive to maintain a strong financial position with emphasis on having a strong balance sheet and increased profitability. Their revenue from operations grew at a CAGR of 23.90% between Fiscal 2017 and Fiscal 2023. The restated profit after tax, grew at a CAGR of 26.81% between Fiscal 2017 and Fiscal 2023.
Single product manufacturing company: : They are a single product manufacturing company and any changes to the paracetamol API industry or product demand will adversely affect revenues, financials and profitability.
Single Manufacturing Facility:: They operate out of a single Manufacturing Facility located at Palghar, Maharashtra and any localized social unrest, natural disaster or breakdown of services or any disruption in production at manufacturing unit could have material adverse effect on business and financial condition.
Strict Quality Requirements: : They are subject to strict quality requirements, regular inspections and audits by customers and any failure to comply with quality standards may lead to cancellation of existing and future orders. Limited Suppliers: They have a limited number of suppliers for raw materials who are highly concentrated in the western region of India. This may require them to procure from other suppliers at higher cost and cause operational interruptions and affect their delivery capacity.
What is the Valiant Laboratories Limited IPO? +
When will the IPO open? +
.What is the lot size of the IPO? +
How to apply for an IPO? +
When will the IPO be allotted? +
When is the IPO listing date? +

Explore Other Products

Rupeezy AppAdvanced charts, advanced Option Chain, instant pay-in & pay-out,margin .Learn More
Rupeezy <> TradingViewEnjoy top-class trading experience enhanced by advanced TradingView charts.Learn More
DockPortfolio analysis, pledge holdings, apply in IPOs & download reports Learn More